newsfilter
← Latest News
Business Wire·

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that the European Commission (EC) has granted